Rare diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs
Blogs
Rare diseases
Six steps for a successful Early Access Program in Europe
Thought Leadership
Rare diseases
Get the free whitepaper: Transitioning from open-label extensions to early access programs
Blogs
Rare diseases
Mitigating risks in early access programmes: A guide for biotech companies
Thought Leadership
Rare diseases
Get the free whitepaper: How early access programs & real-world data help Biotechs succeed
News
Rare diseases
Sciensus partners with Sentynl Therapeutics
News
Rare diseases
Sciensus hosts a webinar with Fierce Biotech
Thought Leadership
Rare diseases
Launching successful patient support programs for rare disease patients across Europe
Blogs
Rare diseases
Packaging and label compliance in Europe: successfully navigating regulations with Sciensus
Blogs
Rare diseases
Planning your EU orphan drug stock management with Sciensus